Source: Annual Congress 2005 - Various aspects of pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Esposito, M. Perrella, D. Micera, E. Conte, F. Perna, M. Gilli, M. Bocchino, A. Sanduzzi (Naples, Italy). Does IFN-g slow progression of idiopathic pulmonary fibrosis (IPF)?. Eur Respir J 2005; 26: Suppl. 49, 2200

Member's Comments

No comment yet.

Related content which might interest you: IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 373s Year: 2007 The circulating metabolome in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Handigrip strenght and dynapenia in patients with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Neutrophil-rich inflammation in induced sputum of patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2001; 18: Suppl. 33, 409s Year: 2001 Aerosolized interferon-gamma (IFN-γ) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007 Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 246s Year: 2007 Analysis of pulmonary function in patients with idiopathic pulmonary fibrosis (IPF): how stable is stable IPF? Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 Idiopathic pulmonary fibrosis (IPF) Source: ERS Course 2016 Year: 2016 Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients? Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases Year: 2017 Enhanced effects of pirfenidone on the early phase of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Towards a better diagnosis of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - Idiopathic pulmonary fibrosis: present understandings and future directions Year: 2010 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2006 - Clinical physiology Year: 2006 Endotrophin is related to disease progression in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease Year: 2011 Inhibition of local fibrinolysis differs between idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (f-NSIP) Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom? Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment Year: 2006 Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009